Altimmune, Inc. ALT
Set alert
2.04 USD -0.10 -4.67%
At close · Oct 30
2.07 +0.03 +1.47%
After hours · Oct 30, 7:12 PM ET
1.99 Day range 2.13
2.04 52-week range 6.18
- YTD
- -43.49%
- 1 year
- -49.88%
- Open
- 2.10
- Prev close
- 2.14
- Mkt cap
- 396.82M
- Vol
- 3.52M
- Avg vol
- 4.05M
- EPS
- -0.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.99
- High
- 2.13
- Forward P/E
- -5.14
- Beta
- 0.07
- Short ratio
- 5.81
- Inst. own
- 56.68%
- Dividend
- 0.00
- Ex-div date
- Jan 19, 2017
- 50-d avg
- 7.91
- 200-d avg
- 7.41
- 1y target
- 22.86
3M chart
Signals (16)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 536.99M
- Enterprise value
- 449.17M
- Trailing P/E
- 0.00
- Forward P/E
- -5.14
- PEG ratio
- 0.00
- Price / sales
- 10326.74
- Price / book
- 4.03
- EPS (TTM)
- -1.57
- Beta
- 0.07
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 52.00K
- Revenue growth
- -98.60%
- Free cash flow
- -45.63M
- Total cash
- 139.38M
- Total debt
- 1.77M
- Return on equity
- -72.96%
- Shares outstanding
- 71.12M
- Short % of float
- 33.04%
- 50-day average
- 7.91
- 200-day average
- 7.41
Analyst view
Consensus: buy
Buy
Price target (mean) 22.86 +1020.4% upside
Now 2.04
- Target (low)
- 12.00
- Target (mean)
- 22.86
- Target (high)
- 28.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.24.
Financials — quick view
ALT Revenue — quarterly 0
ALT Net income — quarterly -22.82M
ALT EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.36 | -0.32 | +0.04 | +11.11% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.35 | -0.01 | -2.94% |
| May 9, 2024 | Mar 1, 2024 | -0.36 | -0.34 | +0.02 | +5.56% |
| Mar 27, 2024 | Dec 1, 2023 | -0.35 | -0.33 | +0.02 | +5.71% |
| Nov 7, 2023 | Sep 1, 2023 | -0.40 | -0.39 | +0.01 | +2.50% |
| Aug 10, 2023 | Jun 1, 2023 | -0.44 | -0.32 | +0.12 | +27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | UBS | init | — | Buy |
| Aug 12, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 25, 2024 | B. Riley Securities | reit | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- altimmune.com
News
- Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
- Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
- Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
- SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets
- Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Your note
Sign in to keep a note on ALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DRUTZ DAVID J | Director | Sale | Aug 18, 2024 | 0 |
| EISENSTADT RICHARD I | Chief Financial Officer | Stock Award(Grant) | Jan 30, 2024 | 45,012 |
| GARG VIPIN K. | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 1, 2024 | 292,028 |
| HARRIS MATTHEW SCOTT | Officer | Stock Award(Grant) | Jul 30, 2024 | 55,119 |
| JORDT RAYMOND M | Officer | Stock Award(Grant) | Jul 30, 2024 | 14,660 |
| ROBERTS M SCOT | Officer | Stock Award(Grant) | Jul 30, 2024 | 43,325 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.69% | 5,466,094 | 41.27M | Sep 29, 2024 |
| Vanguard Group Inc | 7.01% | 4,983,858 | 37.63M | Sep 29, 2024 |
| Ameriprise Financial, Inc. | 5.45% | 3,876,044 | 29.26M | Sep 29, 2024 |
| State Street Corporation | 4.80% | 3,413,827 | 25.77M | Sep 29, 2024 |
| Tang Capital Management, LLC | 3.87% | 2,750,000 | 20.76M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.35% | 1,668,004 | 12.59M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.63% | 2,584,274 | 19.51M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 1,830,974 | 13.82M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.52% | 1,790,759 | 13.52M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.54% | 1,098,135 | 8.29M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 727,869 | 5.50M | Aug 30, 2024 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 0.57% | 406,082 | 3.07M | Jul 30, 2024 |